Clinical Trials on Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation

Total 1148 results

Zhujiang Hospital
Guangdong Xiangxue Precision Medical Technology Co., Ltd.; Xiangxue Life Science... and other collaborators

Completed

To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors

Solid Tumor | Breast Cancer Stage IV | Gastric Cancer Stage IV | Ovarian Cancer Stage IV | Liver Cancer Stage IV | Esophageal Cancer, Stage IV | Bone and Soft Tissue Tumors | Bladder Carcinoma Stage IV | Prostate Carcinoma Stage IV | Thyroid Cancer Stage IV

China
Beijing Tsinghua Chang Gung Hospital

Unknown

Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)

Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)

China
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States, South Africa
Northwestern University
National Cancer Institute (NCI)

Recruiting

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Refractory Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer... and other conditions

United States
VA Office of Research and Development

Withdrawn

Intervention Protocol for Automated Point-of-Care Surveillance of Outpatient Delays in Cancer Diagnosis (PACT CREATE 3)

Breast Cancer | Hepatocellular Carcinoma | Colorectal Cancer | Lung Cancer | Bladder Cancer

United States
The First Affiliated Hospital of Anhui Medical...

Completed

Long-term Heart-specific Mortality in the Presence of Competing Risks Among Patients With Non-metastatic Gastric Adenocarcinoma Undergoing Resection and Chemotherapy (GaCCoR-01)

Long-term Heart-specific Mortality in the Presence of Competing Risks Among Patients With Gastric Adenocarcinoma Undergoing Resection and Chemotherapy
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

Melanoma | Soft Tissue Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Head and Neck Squamous Cell Carcinoma | Bladder Carcinoma | Colon Carcinoma | Pancreatic Carcinoma | Rectal Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma and other conditions

United States
Duke University
University of Wisconsin, Madison

Recruiting

Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)

Carcinoma, Renal Cell | Carcinoma, Urothelial

United States
Fred Hutchinson Cancer Center
SignalOne Bio, Inc.

Terminated

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Urothelial Carcinoma | Metastatic Triple-Negative Breast Carcinoma

United States
Genocea Biosciences, Inc.

Completed

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

Renal Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer | Urothelial Carcinoma | Cutaneous Melanoma

United States
Incyte Corporation

Terminated

Study of INCB086550 in Select Solid Tumors

Melanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Non Small Cell Lung Cancer | Urothelial Cancer

Korea, Republic of, Bulgaria, Hungary, Taiwan, Ukraine
Fusion Pharmaceuticals Inc.

Terminated

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Breast Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma | Liver Cancer | Bladder Carcinoma | Susceptible FGFR3 Genetic Alterations | FGFR3 | FGFR3 Overexpression | FGFR3 Receptor | FGFR3 Protein Overexpression

United States, Australia
Pfizer

Terminated

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

Gastric Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Gastroesophageal Junction Cancer | Urothelial Cancer | Head and Neck Squamous Cell Carcinomas

United States, Japan
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B

Completed

Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Yonsei University

Recruiting

Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA

Prostate Cancer | Bladder Cancer | Renal Cell Cancer | Ureter Cancer

Korea, Republic of
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

China
RenJi Hospital

Recruiting

Preventive Effects of Aspirin as Adjuvant Therapy in Patients With Locally Advanced Renal Cell Carcinoma

Aspirin as Adjuvant Therapy in Patients With Surgically Treated High Risk Renal Cell Carcinoma

China
H. Lee Moffitt Cancer Center and Research Institute

Completed

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

Renal Cell Carcinoma | Non-Small Cell Lung Cancer | NSCLC | Solid Tumor | Metastatic Cancer | Squamous Cell Carcinoma of the Head and Neck | Urothelial Carcinoma | Squamous Cell Carcinoma | Recurrent Cancer

United States
Assistance Publique - Hôpitaux de Paris
Median Technologies

Completed

Identification of Image Phenotypes to Predict Recurrence After Resection of Hepatocellular Carcinoma (LIVERIBIOPSY)

CT Scans Prior to Surgery With a Least 2 Years of Follow-up

France
Gustave Roussy, Cancer Campus, Grand Paris

Terminated

Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab (IIPOP)

Patients With Gastric Peritoneal Carcinomatosis

France
Helsinki University Central Hospital
Karolinska Institutet

Recruiting

Development of Diagnostics and Treatment of Urological Cancers (DEDUCER)

Kidney Cancer | Urothelial Carcinoma | Prostate Carcinoma | Penile Cancer | Testicular Cancer

Finland
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Completed

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

Lymphoma | Metastatic Melanoma | Metastatic Renal Cell Cancer | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm and other conditions

United States
Exelixis

Recruiting

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002)

Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Metastatic Castration-resistant Prostate Cancer

United States, Poland, Spain, Switzerland, Austria, Australia, Belgium, Israel, Italy, New Zealand, France, Germany, United Kingdom
PsiOxus Therapeutics Ltd

Completed

Mechanism of Action Trial of ColoAd1 (MOA)

Resectable Colon Cancer | Resectable Non-small Cell Lung Cancer | Resectable Bladder Cancer | Resectable Renal Cell Carcinoma

Spain
Yonsei University

Recruiting

Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome

Prostate Cancer | Bladder Cancer | Renal Cell Cancer | Ureter Cancer | Urological Malignancies

Korea, Republic of
Celldex Therapeutics

Completed

A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

Renal Cell Carcinoma | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Cholangiocarcinoma | Non-small Cell Lung Cancer | Primary Peritoneal Carcinoma | Hepatic Cancer | Bladder Urothelial Carcinoma | Other Solid Tumors | MSI-H Colorectal Cancer

United States
Hoffmann-La Roche

Completed

A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors (KAMELEON)

Bladder Cancer | Pancreas Cancer | Cholangiocellular Carcinoma

Spain, Italy, Netherlands, Slovakia
Augusta University

Terminated

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Non Small Cell Lung Cancer | Malignant Mesothelioma | Urothelial Carcinoma | Non-squamous Non-small-cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

Epithelioid Mesothelioma | Cholangiocarcinoma, Extrahepatic | Neoplasms With Mesothelin Expression | Adenocarcinoma, Pancreatic

United States
Weill Medical College of Cornell University
Oncolys BioPharma Inc

Terminated

Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease

Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease

United States
Evopoint Biosciences Inc.
Merck Sharp & Dohme LLC

Recruiting

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Carcinoma | Cervical Cancer | Prostate Cancer | Squamous Cell Carcinoma of Head and Neck | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Urothelial Carcinoma | Other Solid Tumors

China
Acrivon Therapeutics
GOG Foundation

Recruiting

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Platinum-resistant Ovarian Cancer | Urothelial Carcinoma | Endometrial Adenocarcinoma

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Not yet recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01)

Cervical Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Renal Pelvis Cancer | Urinary Bladder Neoplasm | Recurrent...

United States
Fifth Affiliated Hospital, Sun Yat-Sen University

Active, not recruiting

Prognostic Prediction of NPC Based on MR Diffusion-weighted Imaging

Patients With Nasopharyngeal Carcinoma

China
BeiGene

Recruiting

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Melanoma | Renal Cell Carcinoma | Urothelial Carcinoma

China
Peking University First Hospital

Recruiting

Fuzheng Nizeng Formula for Chronic Atrophic Gastritis With Low-grade Intraepithelial Neoplasia, a Multicenter Randomized Controlled Trial

Atrophic Gastritis With Low-grade Intraepithelial Neoplasia

China
Xennials Therapeutics Australia Pty Ltd
Pinotbio, Inc.

Terminated

NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma

Advanced Solid Tumor | High-grade Glioma | Platinum-Resistant Ovarian Cancer | Platinum-Resistant Urothelial Carcinoma

Australia
University of Aarhus

Recruiting

Improved Assessment of Response in Metastatic Renal Cell Carcinoma Using Spectral-CT

Renal Neoplasm With Metastasis | Response Evaluation Criteria in Solid Tumors

Denmark
Monopar Therapeutics

Recruiting

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer | Bladder Cancer | Urothelial Carcinoma | Triple-negative Breast Cancer | Solid Tumor, Adult

Australia
Mayo Clinic

Recruiting

Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial

Malignant Solid Neoplasm | Melanoma | Renal Cell Carcinoma | Lung Non-Small Cell Carcinoma | Urothelial Carcinoma | Lung Small Cell Carcinoma

United States
NeoTX Therapeutics Ltd.
AstraZeneca

Active, not recruiting

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Ovarian Cancer | NSCLC | Prostate Cancer | Mesothelioma | Bladder Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Colorectal Cancer Metastatic | Head and Neck Squamous Cell Carcinoma | Urothelial Cancer | Cervical Squamous... and other conditions

Israel
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer

Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary | Recurrent Oral Cavity... and other conditions

United States
Hebei Medical University Fourth Hospital

Not yet recruiting

Clinical Research on the Effect of Aspirin on the Disease Free Survival Rate of Esophageal Carcinoma

Aspirin as an Adjuvant Therapy, to Observe Its Effect on the Disease Free Survival Rate of Patients With Esophageal Squamous Cell Carcinoma

China
University of Nebraska
Bracco Diagnostics, Inc; Philips Medical Systems

Completed

Rapid 10-Minute Liver MRI Protocol in Patients With Suspected Hepatocellular Carcinoma

Hepatitis | Fibrosis of Liver | Underlying Liver Disease | Cirrhosis With Suspicion of Liver Cancer | Lesion on a Prior Ultrasound, CT or Outside MRI

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Fascial Versus Standard Neck Dissection in Patients With N1b Papillary Thyroid Carcinoma (FADO)

Patients With Papillary Thyroid Cancer and N1b Status

Italy
Day One Biopharmaceuticals, Inc.

Recruiting

Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Melanoma | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Thyroid Cancer, Papillary | Pilocytic Astrocytoma | Bladder Urothelial Carcinoma | Non-Small Cell Adenocarcinoma | MEK Mutation | RAS Mutation | Pancreatic Acinar Carcinoma | RAF Mutation | CRAF Gene Amplification | RAF1 Gene Amplification and other conditions

United States, Canada, Korea, Republic of, Spain, Australia, Belgium, France
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Melanoma | Lymphoma | Head and Neck Cancer | Gastric Cancer | Ovarian Cancer | Hepatocellular Carcinoma (HCC) | Lung Cancer | Bladder Cancer | Endometrial Cancer | Solid Tumors | Renal Cell Carcinoma (RCC) | Triple Negative Breast Cancer (TNBC) | UC (Urothelial Cancer) | Microsatellite-instability (MSI) High Colorectal...

United States
Shanghai Fengxian District Central Hospital
Shanghai Yuansong Biotechnology Co., LTD

Recruiting

Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study (YSCH-01)

Melanoma | Breast Cancer | Head and Neck Cancer | Lung Cancer | Bladder Cancer | Cervical Carcinoma | Ovarian Carcinoma

China

Clinical Trials on Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations